Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMI7FNZ)

Drug Name
6-Benzylsulfanyl-9H-purine Drug Info
Synonyms
Purine, 6-(benzylthio)-; 6-Benzothiopurine; 6-Benzyl MP; 724-34-5; 6-(Benzylthio)purine; 6-Benzylmercaptopurine; 6-benzylsulfanyl-9H-purine; 6-Benzyl-MP; SRI 673; NSC 29421; 6-(benzylsulfanyl)-9H-purine; Purine, 6-benzylthio-; 6-((Phenylmethyl)thio)-1H-purine; EINECS 211-965-4; 6-(benzylthio)-9H-purine; AI3-50277; 6-[BENZYLTHIO]-1H-PURINE; 1H-Purine, 6-[(phenylmethyl)thio]-; 1H-Purine, 6-((phenylmethyl)thio)-; 6-[(PHENYLMETHYL)THIO]-1H-PURINE; 6-benzylthiopurine; AC1Q4XUO; CBMicro_000185; 6-(phenylmethylthio)purine
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
93558
CAS Number
CAS 724-34-5
TTD Drug ID
DMI7FNZ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Approved Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Raf messenger RNA (Raf mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MLN2480 DMBR8NF Solid tumour/cancer 2A00-2F9Z Phase 2 [2]
RG7304 DMGFAVQ Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
SPN-803 DM8O2AQ Parkinson disease 8A00.0 Phase 1 [2]
LXH254 DMQE9PS Non-small-cell lung cancer 2C25.Y Phase 1 [4]
ICo-007 DM79W8K Diabetic macular edema 9B71.02 Phase 1 [5]
LErafAON DMNHPOT Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
DEBROMOHYMENIALDISINE DMDLER8 Discovery agent N.A. Investigative [7]
ZM-336372 DMD5JYQ Discovery agent N.A. Investigative [8]
6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine DMDNG8F Discovery agent N.A. Investigative [1]
PLX-ORI3 DMZG1L5 Solid tumour/cancer 2A00-2F9Z Investigative [2]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Stress-activated protein kinase 2a (p38 alpha)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ozagrel DMIGKA1 Xerophthalmia 5B55.Y Phase 4 [9]
Losmapimod DMIL37Z Acute coronary syndrome BA41 Phase 3 [9]
VX-702 DMKJDR6 Coronary artery disease BA80 Phase 2a [10]
VX-745 DMJAEG6 Alzheimer disease 8A20 Phase 2 [11]
Dilmapimod DMBYJ92 Acute lung injury NB32.3 Phase 2 [9]
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [12]
PMID25991433-Compound-F2 DM37VIQ N. A. N. A. Patented [12]
PMID25991433-Compound-L2 DM58UO9 N. A. N. A. Patented [12]
PMID25991433-Compound-L3 DM3LWUR N. A. N. A. Patented [12]
PMID25991433-Compound-L1 DM2135Y N. A. N. A. Patented [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Raf messenger RNA (Raf mRNA) TTAN5W2 RAF1_HUMAN Inhibitor [1]
Stress-activated protein kinase 2a (p38 alpha) TTQBR95 MK14_HUMAN Inhibitor [1]

References

1 Synthesis and biological testing of purine derivatives as potential ATP-competitive kinase inhibitors. J Med Chem. 2005 Feb 10;48(3):710-22.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2184).
3 Clinical pipeline report, company report or official report of Roche.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
6 Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine. Anticancer Drugs. 2004 Mar;15(3):243-53.
7 Aldisine alkaloids from the Philippine sponge Stylissa massa are potent inhibitors of mitogen-activated protein kinase kinase-1 (MEK-1). J Med Chem. 2002 Jan 17;45(2):529-32.
8 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
9 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
10 Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41.
11 Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
12 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.